Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations

Background: Cabozantinib, a tyrosine kinase inhibitor (TKI), is a prevalent second-line (2 L) therapy and was approved for use after progression on TKIs. However, the 1 L treatment setting has changed since the approval of cabozantinib monotherapy in salvage therapy settings. Objective: To assess th...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Arshit Narang, Georges Gebrael, Yeonjung Jo, Vinay Mathew Thomas, Haoran Li, Gliceida Galarza Fortuna, Nicolas Sayegh, Clara Tandar, Nishita Tripathi, Beverly Chigarira, Ayana Srivastava, Chadi Hage Chehade, Blake Nordblad, Benjamin L. Maughan, Neeraj Agarwal, Umang Swami
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	SAGE Publishing 2024-09-01
Σειρά:	Kidney Cancer
Διαθέσιμο Online:	https://doi.org/10.3233/KCA-240016
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!